Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla

Poonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two steps

Adar Poonawalla, CEO, Serum Institute
Poonawalla said that the commitment of his firm exceeded that of the other firms.
BS Web Team New Delhi
2 min read Last Updated : Sep 15 2020 | 4:43 AM IST
Adar Poonawalla, CEO of the Serum Institute of India, has warned that it will take at least four years to make enough Covid-19 vaccines for the entire world, according to an interview in the Financial Times. 

He added that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. “It’s going to take four to five years until everyone gets the vaccine on this planet," said Poonawalla.

According to FT, Poonawalla estimates the world will need 15 billion doses of vaccine if it is taken in two steps. 

Serum Institute has partnered with five international pharmaceutical firms, including AstraZeneca and Novavax, to develop a Covid-19 vaccine and has committed to produce 1 billion doses, of which it has pledged half to India. The company may also partner with Russia’s Gamaleya Research Institute to manufacture the Sputnik vaccine. Poonawalla said that the commitment of his firm exceeded that of the other vaccine producers.

His comments come a day after Union Health Minister Dr Harsh Vardhan said no date had been fixed yet and that the vaccine might be available in the first quarter of 2021. “It may be ready by the first quarter of next year,” the minister said in the first episode of his Sunday Samvaad — a social media interaction programme. 

Serum Institute is the world’s largest vaccine manufacturer by volume, producing 1.5 bn doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.

As part of its agreement with AstraZeneca, the company will aim to produce vaccine doses that cost around $3 for 68 countries and under its agreement with Novavax, for 92 countries.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Serum Institute of IndiaCoronavirus VaccineAstraZenecaHarsh Vardhan

Next Story